Rapport Therapeutics, Inc.
RAPP
$14.77
-$0.16-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -88.31M | -79.70M | -78.31M | -71.85M | -63.02M |
| Total Depreciation and Amortization | 975.00K | 931.00K | 839.00K | 632.00K | 436.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.11M | 11.01M | 15.06M | 12.29M | 11.89M |
| Change in Net Operating Assets | -2.94M | 308.00K | -2.42M | -1.81M | 948.00K |
| Cash from Operations | -76.17M | -67.45M | -64.83M | -60.74M | -49.75M |
| Capital Expenditure | -679.00K | -1.62M | -2.41M | -3.62M | -3.53M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.20M | -105.56M | -167.74M | -277.12M | -224.22M |
| Cash from Investing | 22.52M | -107.18M | -170.14M | -280.73M | -227.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.00K | 159.11M | 159.11M | 159.10M | 159.10M |
| Repurchase of Common Stock | -1.40M | -1.40M | -1.39M | -1.39M | -4.00K |
| Issuance of Preferred Stock | 0.00 | 0.00 | 63.94M | 63.94M | 149.25M |
| Repurchase of Preferred Stock | -- | -29.00K | -29.00K | -35.00K | -35.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -63.00K | 283.00K | 0.00 | -134.00K | -76.00K |
| Cash from Financing | -1.45M | 157.97M | 221.63M | 221.48M | 308.23M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.10M | -16.66M | -13.34M | -119.99M | 30.74M |